新时代的开端:用于中子俘获疗法的肿瘤靶向硼载体。
The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy.
发表日期:2023 Sep 20
作者:
Ting Luo, Wenzhi Huang, Feiyi Chu, Tianyu Zhu, Bin Feng, Shuai Huang, Jing Hou, Liyong Zhu, Shaihong Zhu, Wenbin Zeng
来源:
MOLECULAR PHARMACEUTICS
摘要:
癌症被广泛认定为最毁灭性的疾病之一,需要开发智能诊断技术、靶向治疗和早期预后评估,以确保有效和个体化的治疗。 然而,传统治疗不幸受到限制和严重并发症的增加的限制。在面对这些挑战的情况下,硼中子捕获疗法(BNCT)已成为一种有前途的癌症治疗方法,具有前所未有的精确性,能够选择性地消除肿瘤细胞。 BNCT的独特和有前景的特性有可能彻底改变肿瘤学领域。然而,现有临床药物的固有缺陷和有限供应限制了BNCT技术的临床应用和进展,给BNCT的实际推广和持续进展带来了实质性的障碍。因此,迫切需要开发具有更高硼含量和特异性肿瘤靶向性的高效硼制剂。研究人员旨在通过将肿瘤靶向策略与BNCT相结合,以建立BNCT为一种有效、易得和尖端的癌症治疗方式为最终目标,以解决这一需求。本综述深入探讨了将肿瘤靶向策略与BNCT相结合的最新进展,着重介绍了针对BNCT专门设计的硼制剂的进展情况。通过探索BNCT的现状并强调肿瘤靶向硼制剂的前景,本综述全面概述了BNCT的进展,并突出了其作为癌症转变性治疗选择的潜力。
Cancer is widely recognized as one of the most devastating diseases, necessitating the development of intelligent diagnostic techniques, targeted treatments, and early prognosis evaluation to ensure effective and personalized therapy. Conventional treatments, unfortunately, suffer from limitations and an increased risk of severe complications. In light of these challenges, boron neutron capture therapy (BNCT) has emerged as a promising approach for cancer treatment with unprecedented precision to selectively eliminate tumor cells. The distinctive and promising characteristics of BNCT hold the potential to revolutionize the field of oncology. However, the clinical application and advancement of BNCT technology face significant hindrance due to the inherent flaws and limited availability of current clinical drugs, which pose substantial obstacles to the practical implementation and continued progress of BNCT. Consequently, there is an urgent need to develop efficient boron agents with higher boron content and specific tumor-targeting properties. Researchers aim to address this need by integrating tumor-targeting strategies with BNCT, with the ultimate goal of establishing BNCT as an effective, readily available, and cutting-edge treatment modality for cancer. This review delves into the recent advancements in integrating tumor-targeting strategies with BNCT, focusing on the progress made in developing boron agents specifically designed for BNCT. By exploring the current state of BNCT and emphasizing the prospects of tumor-targeting boron agents, this review provides a comprehensive overview of the advancements in BNCT and highlights its potential as a transformative treatment option for cancer.